{"protocolSection": {"identificationModule": {"nctId": "NCT00778921", "orgStudyIdInfo": {"id": "CSPA100A2304"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone", "officialTitle": "A Randomized, Eight Week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (150/10 mg and 300/10 mg) in Comparison With Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 10 mg Monotherapy"}, "statusModule": {"statusVerifiedDate": "2011-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-10"}, "primaryCompletionDateStruct": {"date": "2009-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-10-23", "studyFirstSubmitQcDate": "2008-10-23", "studyFirstPostDateStruct": {"date": "2008-10-24", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-13", "resultsFirstSubmitQcDate": "2011-02-25", "resultsFirstPostDateStruct": {"date": "2011-03-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-09-20", "lastUpdatePostDateStruct": {"date": "2016-10-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Study Director", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients with hypertension not adequately controlled with amlodipine alone."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Aliskiren", "Amlodipine", "Non-responder to Amlodipine"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 847, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Amlodipine 10 mg", "type": "EXPERIMENTAL", "description": "Amlodipine 10 mg", "interventionNames": ["Drug: Amlodipine 10 mg"]}, {"label": "Aliskiren/Amlodipine 150/10 mg", "type": "EXPERIMENTAL", "description": "Aliskiren/Amlodipine 150/10 mg", "interventionNames": ["Drug: Amlodipine 10 mg", "Drug: Aliskiren 150"]}, {"label": "Aliskiren/Amlodipine 300/10 mg", "type": "EXPERIMENTAL", "description": "Aliskiren/Amlodipine 300/10 mg", "interventionNames": ["Drug: Amlodipine 10 mg", "Drug: Amlodipine 300"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine 10 mg", "description": "Amlodipine 10 mg", "armGroupLabels": ["Aliskiren/Amlodipine 150/10 mg", "Aliskiren/Amlodipine 300/10 mg", "Amlodipine 10 mg"]}, {"type": "DRUG", "name": "Aliskiren 150", "description": "Aliskiren/Amlodipine 150/10 mg", "armGroupLabels": ["Aliskiren/Amlodipine 150/10 mg"]}, {"type": "DRUG", "name": "Amlodipine 300", "description": "Aliskiren/Amlodipine 300/10 mg", "armGroupLabels": ["Aliskiren/Amlodipine 300/10 mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study", "timeFrame": "Baseline and Week 8"}], "secondaryOutcomes": [{"measure": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study", "timeFrame": "Baseline and Week 8"}, {"measure": "Number of Patients With Any Adverse Event and/or Serious Adverse Event in the Double-blind Period by Treatment Group", "timeFrame": "8 weeks"}, {"measure": "Biomarker Assessment at Visit 2 (Single Blind Run in), Visit 5 (Randomization), and Visit 9 (EOS)", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP \u2265 95 mmHg and \\< 110 mmHg at Visits 1 and 2\n* Patients who have been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP \u2265 90 mmHg and \\< 110 mmHg at Visit 2\n* All patients must have a msDBP \u2265 90 mmHg and \\< 110 mmHg at Visit 5 (randomization)\n\nExclusion Criteria:\n\n* Severe hypertension\n* Pregnant or nursing (lactating) women\n* Pre-menopausal women not taking accepted form of birth control\n* Serum potassium \u2265 5.3 mEq/L (mmol/L) at Visit 1\n* History of cardiovascular conditions\n* Uncontrolled Type 1 or Type 2 diabetes mellitus\n* Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with similar chemical structures\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "N", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Investigative Site", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigative Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Investigative Site", "city": "Oslo", "country": "Norway", "geoPoint": {"lat": 59.91273, "lon": 10.74609}}, {"facility": "Investigative Site", "city": "Warsaw", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Investigative Site", "city": "Bratislava", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Investigative Site", "city": "Stockholm", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "Investigative Site", "city": "Ankara", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}]}, "referencesModule": {"references": [{"pmid": "22303911", "type": "DERIVED", "citation": "Pfeiffer D, Rennie N, Papst CC, Zhang J. Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy yen. Curr Vasc Pharmacol. 2012 Nov;10(6):773-80. doi: 10.2174/157016112803520945."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Aliskiren/Amlodipine 300/10 mg", "description": "Oral tablets of combination aliskiren/amlodipine 300/10 mg taken once daily with water in the morning"}, {"id": "FG001", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "Oral tablets of combination aliskiren/amlodipine 150/10 mg taken once daily with water in the morning"}, {"id": "FG002", "title": "Amlodipine 10 mg", "description": "Oral capsules of amlodipine 10 mg taken once daily with water in the morning"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "279"}, {"groupId": "FG001", "numSubjects": "285"}, {"groupId": "FG002", "numSubjects": "283"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "261"}, {"groupId": "FG001", "numSubjects": "266"}, {"groupId": "FG002", "numSubjects": "255"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "19"}, {"groupId": "FG002", "numSubjects": "28"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "14"}]}, {"type": "Abnormal Laboratory Value(s)", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Abnormal Test Procedure Result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Unsatisfactory therapeutic response", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Patient No Longer Requires Study Drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Patient withdrew request", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "6"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Administrative Problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Not treated", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren/Amlodipine 300/10 mg", "description": "Oral tablets of combination aliskiren/amlodipine 300/10 mg taken once daily with water in the morning"}, {"id": "BG001", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "Oral tablets of combination aliskiren/amlodipine 150/10 mg taken once daily with water in the morning"}, {"id": "BG002", "title": "Amlodipine 10 mg", "description": "Oral capsules of amlodipine 10 mg taken once daily with water in the morning"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "279"}, {"groupId": "BG001", "value": "285"}, {"groupId": "BG002", "value": "283"}, {"groupId": "BG003", "value": "847"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.2", "spread": "10.19"}, {"groupId": "BG001", "value": "54.4", "spread": "10.70"}, {"groupId": "BG002", "value": "54.3", "spread": "10.92"}, {"groupId": "BG003", "value": "54.6", "spread": "10.60"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "116"}, {"groupId": "BG001", "value": "113"}, {"groupId": "BG002", "value": "99"}, {"groupId": "BG003", "value": "328"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "163"}, {"groupId": "BG001", "value": "172"}, {"groupId": "BG002", "value": "184"}, {"groupId": "BG003", "value": "519"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study", "populationDescription": "full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Aliskiren/Amlodipine 300/10 mg", "description": "Oral tablets of combination aliskiren/amlodipine 300/10 mg taken once daily with water in the morning"}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "Oral tablets of combination aliskiren/amlodipine 150/10 mg taken once daily with water in the morning"}, {"id": "OG002", "title": "Amlodipine 10 mg", "description": "Oral capsules of amlodipine 10 mg taken once daily with water in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "277"}, {"groupId": "OG001", "value": "281"}, {"groupId": "OG002", "value": "279"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.99", "spread": "0.462"}, {"groupId": "OG001", "value": "-8.95", "spread": "0.460"}, {"groupId": "OG002", "value": "-7.23", "spread": "0.459"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study", "populationDescription": "full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Aliskiren/Amlodipine 300/10 mg", "description": "Oral tablets of combination aliskiren/amlodipine 300/10 mg taken once daily with water in the morning"}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "Oral tablets of combination aliskiren/amlodipine 150/10 mg taken once daily with water in the morning"}, {"id": "OG002", "title": "Amlodipine 10 mg", "description": "Oral capsules of amlodipine 10 mg taken once daily with water in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "277"}, {"groupId": "OG001", "value": "281"}, {"groupId": "OG002", "value": "279"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-14.42", "spread": "0.684"}, {"groupId": "OG001", "value": "-11.01", "spread": "0.681"}, {"groupId": "OG002", "value": "-8.20", "spread": "0.680"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Any Adverse Event and/or Serious Adverse Event in the Double-blind Period by Treatment Group", "populationDescription": "Analysis: Intention to Treat (ITT) Imputation Technique: Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren/Amlodipine 300/10 mg", "description": "Oral tablets of combination aliskiren/amlodipine 300/10 mg taken once daily with water in the morning"}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "Oral tablets of combination aliskiren/amlodipine 150/10 mg taken once daily with water in the morning"}, {"id": "OG002", "title": "Amlodipine 10 mg", "description": "Oral capsules of amlodipine 10 mg taken once daily with water in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "279"}, {"groupId": "OG001", "value": "283"}, {"groupId": "OG002", "value": "281"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "87"}, {"groupId": "OG001", "value": "99"}, {"groupId": "OG002", "value": "92"}]}]}]}, {"type": "SECONDARY", "title": "Biomarker Assessment at Visit 2 (Single Blind Run in), Visit 5 (Randomization), and Visit 9 (EOS)", "reportingStatus": "NOT_POSTED", "timeFrame": "12 weeks"}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Aliskiren 300mg/ Amlodipine 10mg", "description": "Aliskiren 300mg/ Amlodipine 10mg", "seriousNumAffected": 4, "seriousNumAtRisk": 279, "otherNumAffected": 31, "otherNumAtRisk": 279}, {"id": "EG001", "title": "Aliskiren 150mg/ Amlodipine 10mg", "description": "Aliskiren 150mg/ Amlodipine 10mg", "seriousNumAffected": 1, "seriousNumAtRisk": 283, "otherNumAffected": 35, "otherNumAtRisk": 283}, {"id": "EG002", "title": "Amlodipine 10mg", "description": "Amlodipine 10mg", "seriousNumAffected": 0, "seriousNumAtRisk": 281, "otherNumAffected": 40, "otherNumAtRisk": 281}], "seriousEvents": [{"term": "Lymphoid tissue hyperplasia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 283}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 281}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 283}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 281}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 283}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 281}]}, {"term": "Renal artery stenosis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 283}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 281}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 283}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 281}]}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 283}, {"groupId": "EG002", "numAffected": 25, "numAtRisk": 281}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 283}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 281}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}